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ABSTRACT
Background: Pathological alterations in nutritional status may develop in Chronic Obstructive Pulmonary
Disease (COPD) patients through production of inflammatory cytokines and inadequate diet. Objective:
The aim of our study was to determine the correlation between nutritional status and quality of life of
COPD patients. Methods: We evaluated the nutritional status of COPD patients of Hungarian National
Koranyi Institute for Pulmonology using the Malnutrition Universal Screening Tool (MUST) and
bioelectrical impedance analysis (BIA) between January 1 and June 1, 2019. Lung function, physical fitness,
and respiratory muscle strength were included in the assessment. Results: Fifty patients (mean age was 66.3
± 9.6 years) participated in our study. Mean body mass index (BMI) was 26.2 ± 6.1 kg/m2 and mean fat-
free mass index (FFMI) was 16.8 ± 2.4 kg/m2. Overweight patients had better lung function values (FEV1ref
%: 46.3 ± 15.2) than normal (FEV1ref%: 45.1 ± 20.9) and underweight patients (FEV1ref%: 43.8 ± 16.0).
The Modified Medical Research Council Dyspnea Scale (mMRC) was significantly associated with various
parameters; strongest correlation was found with FFMI (r5 0.537, P < 0.001), skeletal muscle mass index
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(SMMI) (r 5 0.530, P < 0.001), and 6-minute walking distance (6MWD) (r 5 0.481, P < 0.001).
Conclusions: Our results indicate that malnourished COPD patients may have reduced lung function and
lower quality of life compared to normal weight patients. Thus, our findings suggest that nutritional
therapy be included in the treatment of COPD patients combined with nutritional risk screening and BIA
during the follow-up.
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chronic obstructive pulmonary disease, bioelectrical impedance analysis, body-mass index, fat-free mass index,
nutritional status
INTRODUCTION
The pathogenesis and clinical manifestations of Chronic Obstructive Pulmonary Disease
(COPD) appear typically as pulmonary inflammation and structural abnormalities; yet in several
cases, systemic lesions may also be present [1]. Evaluation of nutrition, diet, and body
composition is also considered highly important in the treatment of COPD patients [2]. COPD
often correlates with one or more comorbidities (such as hypertension, atherosclerosis, chronic
heart failure, lung cancer, osteoporosis, and depression), which worsen the underlying disease
[3, 4]. Muscle weakness and atrophy as well as weight loss are very common in COPD, and are
associated with changes in body composition [5]. Low body mass index (BMI <21 kg/m2) leads
to higher mortality and reduced quality of life [6]. Low body weight consequently appears to be
an independent marker of poor disease outcome. However, BMI is not its exclusive indicator,
thus it is recommended to use it together with fat-free mass (FFM) and fat-free mass index
(FFMI) [7].
Low BMI is measured in 10–15% of patients with mild-to-moderate disease, and in
50% of patients with advanced-stage disease and chronic respiratory failure [8]. Exact
causes of weight loss are not clearly identified thus far, although fast metabolic rate un-
compensated by adjusted calorie intake is considered to play an essential role in its
development [8].
Numerous techniques are used to assess body composition in COPD, including bioelectrical
impedance analysis (BIA), anthropometry, dual-energy X-ray absorptiometry (DEXA) and more
advanced imaging technologies, such as magnetic resonance imaging, computed tomography
and high resolution computed tomography [9]. BIA is a bedside method approved in numerous
clinical studies, as it has various advantages due to its portability, affordability, and user-
friendliness [10]. This method applies a low alternating current through electrodes attached to
the wrist and ankle. The resistance measured is used to calculate the lean body mass (LBM). BIA
is more reliable for identifying nutritional excesses if compared with traditional anthropometric
approaches [10].
The number of studies focusing on analyzing body composition is continuously
increasing. The theory that muscles do more than mechanical movement and storing proteins
and carbohydrates have become an important research topic. Musculoskeletal tissue acts as an
autocrine, paracrine, and endocrine organ, which has an effect on its own operation and that
of adjacent and distant organs [11]. Researchers demonstrated that skeletal muscle fibers
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produce hormone-like myokines for physical activity, such as interleukin-6,-8,-15, brain-
derived neurotrophic factor, and leukemia inhibitory factor (LIF), which also have anti-in-
flammatory ability [12]. Additionally, growing evidence supports the role for metabolic in-
terventions and age-related pathologies to modulate cellular and molecular pathways in
skeletal muscle [13].
From a clinical aspect, progressive impairment of the respiratory function in COPD is
associated with altered nutritional status, which is a serious problem in itself, and its conse-
quences also influence the natural course of COPD. Routine treatment of COPD patients does
not include body composition tests, although the course of the disease justifies it, since the
production of inflammatory cytokines can shift metabolic balance towards catabolism.
Furthermore, lower physical activity and restricted diets can also be observed [14, 15]. The
factors listed, individually and in combination, further increase the risk of total weight and/or
fat-free weight loss. Moreover, poor nutritional status increases the morbidity rate, the fre-
quency of infections, and the length of hospital stay decreases the patients’ quality of life [16].
Our research aimed to study the association between low body weight and the severity of
COPD, and to determine the patients’ nutritional status and its correlation with their quality
of life.
METHODS
Study design and population
A cross-sectional study was performed among COPD patients of the Hungarian National
Koranyi Institute for Pulmonology. All patients were given oral and written information
on the study and they signed statements of consent. Participation was voluntary. The
study was approved by the regional Ethical Committee (License Number: TUKEB 44402-
2/2018/EKU) and complies with the Declaration of Helsinki. Inclusion criteria were age
≥40 years and the concurrent diagnosis of COPD (post-bronchodilation FEV1/FVC<70%).
Exclusion criteria were implanted pacemaker, any implantation or prosthesis, pregnancy,
existence of severe dehydration, edema, or other chronic diseases (e.g. cancer or endo-
crine disorders).
Measurements
In our sample (n 5 50) for combined nutrition status risk screening a Malnutrition
Universal Screening Tool (MUST) questionnaire [17] was used with bioelectric impedance
analysis (BIA) based on body composition analysis. The following parameters were
included in the evaluation of the MUST questionnaire: BMI (0 points, if BMI is over 20 kg/
m2; 1 point, if BMI was between 18.5 and 20; and 2 points, if BMI was less than 18.5 kg/
m2), amount of weight loss (0 points, if it was less than 5%; 1 point, if it was 5–10%; 2
points, if it was over 10%), and the effect of any acute disease on food intake (0 points, if
there was no acute disease and the food intake was satisfactory; 2 points in any other case).
Patients were considered to be at low risk if they scored 0 points, medium risk was 1 point,
and high risk was 2–6 points. One of the limitation of the MUST questionnaire is that it is
based only on BMI and does not take into account the body composition. To compensate
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it, we also performed a body composition analysis with an InBody170 multi-frequency
medical device, which measures body mass and calculates body fat percentage, muscle
percentage, water content, and body mass index. Patients were instructed not to eat or
drink and not to perform strenuous physical activity for at least 2 h before the mea-
surement. The analysis was performed after discharging urine and stool, and preferably not
during menstruation. Patients were asked to undress down to their underwear, remove
jewelry, and stand barefoot. We also paid attention to posture (position at the measuring
points, arms not touching the body) and room temperature. Total body weight, derived
BMI, lean mass (FFM 5 lean mass þ bone mineral density), and derived FFMI (FFMI 5
FFM/height2) were calculated. Malnourishment was defined as FFMI <15 kg/m2 for fe-
males and <16 kg/m2 for males, which are considered as clinically useful proxies in the age
range of most COPD patients [18, 19]. Based on the BMI, COPD patients were categorized
as normal weight (BMI ≥ 21 and <25 kg/m2), underweight (BMI <21 kg/m2) and over-
weight (BMI ≥ 25).
Spirometry analysis and 6-minute walking distance (6MWD) were also part of the mea-
surements. Spirometry included the post-bronchodilator forced expiratory volume in the first
second (FEV1). The results were expressed as a percentage of the predicted values. For the
assessment of 6MWD [20], patients were instructed to walk up and down the hallway for a
maximum of 6 min.
To measure quality of life, we used the Hungarian, disease-specific 40-question version of the
Saint George’s Respiratory Questionnaire (SGRQ-C) [21, 22]. Factors that influence quality of
life were divided into three categories: symptoms, activity, and the impact of lung disease on
daily lifestyle. Weighted values of specific answers were used to calculate the scores for each
category and the total sum. Higher scores of this questionnaire indicate lower quality of life.
Patients administered the questionnaire in controlled conditions under the coordinator’s su-
pervision. The severity of dyspnea was rated according to the Modified Medical Research
Council Dyspnea Scale (mMRC) [23, 24]. Based on the outcomes, patients were assigned to
three categories: mild dyspnea (mMRC score of 0–1) moderate dyspnea (mMRC score of 2–3)
and severe dyspnea (mMRC score of 4). Patients also completed the COPD Assessment
Test (CAT) questionnaire, which contains eight questions about of the patients’ health
status. A maximum of 40 points can be achieved with higher scores indicating lower quality
of life [25].
Statistical analysis
Since the majority of data did not show normal distribution (verified by Sapphiro-Wilk test),
non-parametric statistical methods were used in our study. Descriptive statistics and continuous
variables were interpreted by averages with standard deviations (SD) and 95% confidence in-
tervals. Categorical data were presented with case numbers and proportions. Mann-Whitney
tests were used to detect the differences of continuous variables between the two groups. In the
case of more than two groups, Kruskal-Wallis ANOVA tests were used. Frequency differences of
categorical variables were examined by Fisher’s exact test. Spearman’s correlation tests were used
to indicate the relationship between continuous variables, which were interpreted by Spearman’s
rho and P values. The statistical analysis was conducted with STATA SE-10.0 (StataCorp,
College Station, TX).
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RESULTS
We performed combined nutrition risk screening in our sample (n 5 50). 36 (72%) patients
were not diagnosed with any risk of developing abnormal nutritional status either via the
MUST or via the BIA method. However, MUST reported risk for 9 persons (18%), and BIA for
14 persons (28%). Patient characteristics (mean ± SD): 66.3 ± 9.6 years of age; 26.2 ± 6.1 kg/m2
BMI; 46.0 ± 9.7 kg fat-free body mass (FFM); and 16.8 ± 2.4 kg/m2 FFMI. Patient characteristics
are shown in Tables 1 and 2.
Patients were classified into A, B, C, D severity groups based on the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) complex stage classification; as a result, 4% (n 5 2)
Table 1. Characteristics of the patients
N 5 50 Mean value Standard deviation 95% CI
Age (years) 66.30 9.66 [63.56–69.04]
FEV1 (ref%) 45.52 16.18 [40.92–50.12]
6MWD (meters) 289.48 110.48 [258.08–320.88]
CAT (points) 22.12 10.24 [19.21–25.03]
SGRQ-C-symptoms 63.52 22.63 [57.08–69.95]
SGRQ-C-activity 62.95 26.92 [55.30–70.60]
SGRQ-C-impact 54.12 26.87 [46.49–61.76]
SGRQ-C-total score 58.41 23.37 [51.77–65.05]
FEV1: forced expiratory volume in 1 s post-bronchodilator; 6MWD: six-minute walk distance; CAT:
COPD Assessment Test; SGRQ-C: Saint-George Respiratory Questionnaire for COPD patients.
Table 2. Body composition measurements
N 5 50 Mean value Standard deviation 95% CI
BMI (kg/m2) 26.26 6.17 [24.51–28.02]
FFM (kg) 46.00 9.70 [43.24–48.75]
FFMI (kg/m2) 16.83 2.44 [16.13–17.52]
SMM (kg) 24.96 5.82 [23.30–26.61]
SMMI (kg/m2) 9.11 1.50 [8.69–9.53]
BFM (kg) 25.26 12.58 [21.68–28.83]
PBF (%) 33.75 11.96 [30.45–37.15]
TBW (kg) 33.81 7.17 [31.77–35.85]
WHR 0.93 0.09 [0.90–0.95]
Muscle control 3.06 4.09 [1.89–4.22]
Fat control 13.43 11.98 [16.83–10.03]
Basal metabolic rate 1,363.72 209.49 [1,304.18–1,423.26]
Fitness score 63.84 8.69 [61.37–66.32]
BMI: body mass index; FFM: fat free mass; FFMI: fat-free mass index; SMM: skeletal muscle mass; SMMI:
skeletal muscle mass index; BFM: body fat mass; PBF: percent body fat; TBW: total body water; WHR:
waist-hip ratio; SD: Standard deviation.
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of them were put into group A, 28% (n 5 14) into group B, 16% (n 5 8) into group C, whereas
more than half of them (52%, n 5 26) belonged in group D. More than half (n 5 14) of the
patients in severity group D were malnourished, and one third of the patients in group B (n5 3)
had this condition (malnutrition defined as FFM index <15 kg/nm2 in women and <16 kg/nm2
in men).
The mean of body fat percentage in males was 27.8% (±11.1), and the mean body fat
percentage in females was 37.4% (±11.1). 26.3% of men had low body fat, 5.2% of them
had normal and 68.5% had high values, whereas 12.9% of female patients had low, 9.7%
normal, and 77.4% high body fat values. The mean muscle percentage was 39.6% (±6.0) in
men and 33.3% (±5.4) in women. 58% of males had a low value of muscle percentage, and
42% of them were in the high range. 65% of women had low, 13% normal, and 22% high
muscle percentage values. When examining the relationship between muscle percentage
and lung function, patients with higher muscle percentage showed better lung function
values.
Respiratory distress was more frequent in patients with low FFMI compared to those with
normal FFMI (FEV1ref%: 38.9 versus 48.6, P 5 0.023), and the 6MWD also showed significant
difference [6MWD (m): 222.7 versus 320.8, P 5 0.002], as shown in Table 3. The mean BMI
values calculated from body weight and height showed that 14.0% (n 5 7) of patients had
normal, 26.0% (n 5 13) low and 60.0% (n 5 30) high values. Patients with low body weight
(BMI<21 kg/m2) had worse activity, effect, symptoms and total SGRQ-C scores, and they also
had worse FEV1 values, and shorter 6MWD values than patients in the normal or overweight
category, as shown in Table 4.
The mMRC dyspnea scale correlated significantly with various parameters (Table 5): the
strongest correlation was found with FFMI (r 5 0.537, P < 0.001), skeletal muscle mass
index (SMMI) (r 5 0.530, P < 0.001) and 6MWD (r 5 0.481, P < 0.001). Correlation
between FFMI, respiratory symptoms, and exercise capacity was also found, and FFMI was
significantly correlated with FEV1 (r 5 0.370, P < 0.001) and 6MWD as well (r 5 0.531, P <
0.001), as shown in Table 6. We found a statistically significant relationship between CAT
points and FFMI (r 5 0.4906, P 5 0.0003) and CAT points with SMMI (r 5 0.4532, P 5
0.0009).
Table 3. The characteristics with low FFMI versus those with normal FFMI
N 5 50 Low FFMI Normal FFMI P-value
FEV1 (ref%) 38.89 (±11.63) 48.65 (±16.61) 0.023
Body mass index (kg/m2) 21.07 (±5.11) 28.71 (±5.46) <0.001
Fat-free mass index (kg/m2) 14.18 (±0.76) 18.07 (±1.83) <0.001
Fat mass index (kg/m2) 6.89 (±4.81) 10.65 (±4.58) 0.008
6MWD (meters) 222.75 (±126.01) 320.88 (±89.65) 0.002
CAT (points) 28.50 (±5.42) 19.12 (±10.91) 0.003
FEV1: forced expiratory volume in 1 s post-bronchodilator; 6MWD: six-minute walk distance; CAT:
COPD Assessment Test; P < 0.05 means the two indicators were significantly correlated.
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Table 5. Correlation between mMRC dyspnea scale and other parameters
N 5 50 r P-value
FEV1 (ref%) 0.330 0.019
BMI (kg/m2) 0.162 0.262
FFMI (kg/m2) 0.537 <0.001
SMMI (kg/m2) 0.530 <0.001
PBF (%) 0.190 0.187
WHR 0.060 0.677
6MWD (meters) 0.481 <0.001
mMRC: Modified Medical Research Council Dyspnoea Scale; FEV1: forced expiratory volume in 1 s post-
bronchodilator; BMI: body mass index; FFMI: fat-free mass index; SMMI: skeletal muscle mass index; PBF:
percent body fat; WHR: waist-hip ratio; 6MWD: six-minute walk distance; P < 0.05 means the two
indicators were significantly correlated.








Mean age (years) (SD) 65.9 ± 10.8 59.7 ± 11.8 68.0 ± 8.1
Males (n, %) 5 (38.4) 4 (57.1) 10 (33.3)
Women (n, %) 8 (61.5) 3 (42.8) 20 (66.6)
FEV1 (ref%) 43.8 ± 16.0 45.1 ± 20.9 46.3 ± 15.2
6MWD (meters) 276.4 ± 123.5 280.2 ± 117.0 297.2 ± 106.3
Mild dyspnea (mMRC score of
0–1)
3 (23.0) 2 (28.5) 14 (46.6)
Moderate dyspnea (mMRC
score of 2–3)
9 (69.2) 5 (71.4) 9 (30.0)
Severe dyspnea (mMRC score
of 4)
1 (7.6) 0 (0) 7 (23.3)
Quality of Life (mean, SD) 25.8 ± 6.6 25.7 ± 5.2 19.7 ± 11.7
Total score on SGRQ-C 67.6 ± 21.5 63.9 ± 9.7 53.1 ± 25.2
Impact score on SGRQ-C 64.7 ± 26.0 62.4 ± 14.2 47.6 ± 28.0
Activity score on SGRQ-C 70.6 ± 25.7 63.5 ± 10.5 59.4 ± 29.7
Symptom score on SGRQ-C 71.4 ± 15.2 69.9 ± 18.6 58.6 ± 25.2
SGRQ-C: Saint-George Respiratory Questionnaire for COPD patients; mMRC: Modified Medical Research
Council Dyspnoea Scale; FEV1: forced expiratory volume in 1 s post-bronchodilator; BMI: body mass
index; 6MWD: six-minute walk distance; SD: Standard deviation.
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DISCUSSION
The aim of our study was to assess the nutritional status of 50 COPD patients and describe its
relationship with quality of life. Based on our results, the nutritional status of COPD patients is a
significant prognostic factor for the course of their disease. MUST reported a high risk of
malnutrition in 9 persons (18%), whereas 14 persons fell in the same category (28%) based on
the results of the BIA. In addition, more than half of the patients (n 5 14) in the ‘GOLD D’
severity group were malnourished. Patients with low BMI had lower overall SGRQ-C scores,
worse respiratory functions, and shorter 6MWD compared to patients in normal and overweight
ranges. Examining the correlation of body muscle percentage and lung function, we found that
patients who had higher body muscle percentage showed better lung function values. Addi-
tionally, the mMRC Dyspnea Scale was also significantly correlated with various parameters,
such as FFMI, SMMI, and 6MWD, whereas significant correlations were found between FFMI
and FEV1 (r 5 0.370, P < 0.001), and between FFMI and 6MWD (r 5 0.531, P < 0.001) as well.
In the general population, 25–40% of all patients with COPD have low body weight and most
of them have a very low FFMI as well [26], which is in line with the results of our study (n5 14,
28%). FFMI is a major indicator of exercise capacity. In our study, the 6MWD was correlated
with FFMI, which may indicate that COPD patients are more prone to develop exercise
intolerance because of skeletal muscular cell atrophy [27, 28]. Since FFMI describes muscle mass
more accurately than other indices [29], it should be considered as an essential tool during
pulmonary rehabilitation [30].
We found that impaired FFM is more frequent in female than in male COPD patients.
Engelen et al. also reported higher prevalence of nutritional depletion in women (35%) than men
(16%) [31], whereas Schols et al. found 42 and 34%, respectively [32]. Female patients with more
intense and severe forms of COPD can show higher nutritional depletion, which can be
explained as a gender-specific risk factor in COPD; additionally, they also have a faster onset of
air dysfunction than men [33].
Pathophysiology of malnutrition in COPD is not fully cleared yet. However, certain factors,
such as the number of exacerbations may play an essential role in the changes of body
composition. Exacerbations increase serum levels of local and systemic inflammatory markers
(Tumor necrosis factor alpha (TNF-a), IL-1, IL-6, IL-8), which have been proven to result not
only in vascular and endothelial injury and dysfunction [34]. TNF-a (cachectin), a key player in
Table 6. Correlation between FFMI and other parameters
N 5 50 r P-value
Age (years) 0.123 0.395
FEV1 (ref%) 0.370 <0.001
6MWD (meters) 0.531 <0.001
mMRC 0.537 <0.001
Exacerbations 0.312 <0.001
FFMI: fat-free mass index; FEV1: forced expiratory volume in 1 s post-bronchodilator; 6MWD: six-minute
walk distance; mMRC: Modified Medical Research Council Dyspnoea Scale; P < 0.05 means the two
indicators were significantly correlated.
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systemic inflammation may be a link between comorbidities (muscle loss, type 2 diabetes,
osteoporosis, atherosclerosis) in COPD [35], and is also associated with the risk of mortality
[36]. It is produced by many cell types (both immune and non-immune cells) and acts through
its cell surface receptors (TNFR1 and TNFR2), which can be found in most tissues and cells. It
has several functions: it stimulates inflammatory processes, induces apoptosis and activates
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB), and these result in a
decreased expression of myoblast determination protein 1 (MyoD), which plays a role in muscle
differentiation [37]. Activated NF-kB is able to inhibit the proteasome subunit (in the ubiquitin-
proteasome pathway), which leads to skeletal muscle atrophy. Because of its highly diversified
effects on many inflammatory processes in COPD, TNF-a is a useful new biomarker and
therapeutic target in the treatment of muscle atrophy.
Nutritional status is an important factor in the development of COPD, and the relationship
is bidirectional [38]. Malnutrition and muscle atrophy are independent negative determinants of
survival among COPD patients [39]. These patients, and in particular patients with severe
condition have been shown to be at risk of malnutrition as the disease progresses, which has the
potential that early intervention in patients with low BMI or muscle atrophy may reduce disease
progression and improve survival in COPD patients [40]. Increasing body weight improves
respiratory muscle efficiency, stronger respiratory muscles may reduce the possibility of acute
exacerbations, and also improve ventilation and load capacity [8, 41–43].
Reduction of BMI and FFMI are independent risk-factors of COPD mortality. Studies suggest
that BMI is only weakly related to the severity of COPD, and thus affects the BODE index (body
mass index, airflow obstruction, dyspnea, and exercise index) less prominently. FFMI may be a
more convenient variable in the multidimensional evaluation of patients. The FODEP index,
which takes into consideration FFMI, FEV1ref%, mMRC scale, 6MWD and maximal inspiratory
pressure (MIP) results, may be a more appropriate indicator to predict COPD patient outcomes.
One unit of change in FODEP index 1.55-fold increased mortality of COPD patients [44].
Limitations of our study include the low number of cases and their single-center involve-
ment. Investigation of pro-inflammatory cytokines (IL-1b, IL-6, IL-8, IL-10, IL12p70 and TNF-
a) has not yet been validated in everyday practice due to significant variability, partly because of
the difficulties of the sampling technique, partly because they are present in very low concen-
trations. Our future plans include long-term follow-up of patients with measuring and testing of
circulating inflammatory parameters, cytokines for COPD outcome.
CONCLUSION
COPD patients are at higher risk of developing pathological nutritional status due to the inflam-
matory nature of the disease and inadequate diet. Low body weight and/or low fat-free body weight
have a significant impact on the progress of COPD and the length of hospital stay. Due to the high
risk of developing malnutrition, screening of COPD patients’ nutritional status with the combination
of MUST and BIA methods should be implemented in outpatient care settings as well. For screened
patients, regular monitoring of nutritional therapy as often as 6–12 months is advised. Nutritional
status assessment should focus not only on quantitative variables (body weight and BMI) but also on
the parameters of body composition (FFM, FFMI). Nutritional therapy may improve the quality of
life of COPD patients significantly, as – in addition to its beneficial respiratory effects – it can also
positively influence other comorbidities, such as cardiovascular and metabolic diseases.
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LIST OF ABBREVIATIONS
6MWT six-minute walk test
BDNF Brain-derived neurotrophic factor
BIA bioelectrical impedance analysis
BMI body mass index
BW body weight
CAT COPD Assessment Test
COPD Chronic Obstructive Pulmonary Disease
DEXA dual-energy X-ray absorptiometry
GOLD Global Initiative for Chronic Obstructive Lung Disease
FEV1 forced expiratory volume in the first second
FFM fat-free mass
FFMI fat-free mass index
FM fat mass
FMI fat mass index




LBM lean body mass
LIF leukemia inhibitory factor
MIP maximal inspiratory pressure
mMRC Modified Medical Research Council Dyspnea Scale
MUST Malnutrition Universal Screening Tool
MyoD myoblast determination protein 1
NF-kB nuclear factor kappa-light-chain-enhancer of activated B cells
PBF percent body fat
SGRQ-C St. George’s respiratory questionnaire for COPD patients
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SMM skeletal muscle mass
SMMI skeletal muscle mass index
TNF-a tumor necrosis factor alpha
TNFR1 Tumor necrosis factor receptor 1
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